The Effect of Metoprolol in the Treatment of Chronic Heart Failure.

Objective To study the efficacy and safety of metoprolol in the treatment of chronic heart failure. Methods Eighty-Seven Patients were divided into two groups. The NYHA class ification was from Ⅱto Ⅳ(in cluding Ⅱin 15 cases, Ⅲ in 61cases and Ⅳ in 11cases); Their ejection 44%. In a basic medical treatment digitalis diuretics and ACE-I metoprolol titated from low dose(6.25mg bid) to the target dose. The target dose of 50 mg per day. They were randomly divided into the follow-up period of 6 to 18 months of the metoprolol group and the control group. The color sonograhy determination of left ventricular function and volume data. Results after 6 to 18 months, the treatment group symptom scores and functional classification improved by increased left ventricular ejection reflex(23.42 ± 6.1) ~(43.64 ± 4.7)%(P=0.0013).both the decreased left ventricular end-systolic and the decreased left ventricular end-diastolic volume was from [(146.42±30.43)mL to(69.67±14.38) mL, P=0.0027) ],and form [(189.86±29.8)mL to(117.81±19.13) mL, P=0.0038].In metoprolol group 58 patients(60.4%)were tolerant target does(50mg/d).All the patients hadn't special side effect.The common symptom was dizzinessNo significant changes of liver and kidney function, blood glucose, blood lipids, electrolytes, blood in the metoprolol group. The conclusion is based on the standard of medical treatment, metoprolol can improve left ventricular function, left ventricular remodeling in patients with chronic heart failure, metoprolol treatment of chronic heart failure treatment is safe and effective.